Speaker
Description
The global adoption of targeted alpha therapy (TAT) using actinium-225(²²⁵Ac)-labeled radiopharmaceuticals is rapidly expanding, driving an urgent need to scale up ²²⁵Ac production and improve supply reliability. Among potential production methods, accelerator-based high-energy proton irradiation of thorium-232(²³²Th) targets via the ²³²Th(p,x)²²⁵Ac reaction represents a promising and sustainable approach. However, achieving large-scale ²²⁵Ac production through this route requires addressing key technological challenges, including the development of high-power proton beams (100–150 MeV) and robust targetry systems.
To address these challenges, the Institute of Modern Physics, Chinese Academy of Sciences (IMP, CAS), is constructing a dedicated demonstration facility—the Isotope Pharmaceutical production platform based on Superconducting Accelerator Facility for Effective therapy (IP-SAFE). Powered by a state-of-the-art Superconducting Radio Frequency (SRF) linear accelerator, this advanced facility will deliver a high-performance 115 MeV Continuous Wave (CW) proton beam with an intensity of 0.5–1 mA to irradiate ²³²Th targets. This paper provides an overview of the IP-SAFE project, highlights the recent progresses.
| Paper status | No proceeding file submitted. |
|---|